HBV and the importance of TLR9 on B cell responses

Issam Tout; Marie Marotel; Isabelle Chemin; Uzma Hasan; Issam Tout; Marie Marotel; Isabelle Chemin; Uzma Hasan

doi:10.3934/Allergy.2017.3.124

AIMS Allergy and Immunology

2017, Volume 1, Issue 3: 124-137. doi: 10.3934/Allergy.2017.3.124

Previous Article Next Article

Review Topical Sections

HBV and the importance of TLR9 on B cell responses

1.
Centre International de recherche en Infectiologie, CIRI, Inserm, U1111, Lyon, France
2.
Université Claude Bernard Lyon 1, Lyon, France
3.
CNRS, UMR5308, Lyon, France
4.
École Normale Supérieure de Lyon, Université Lyon, France
5.
Hospices Civils de Lyon, France
6.
Cancer Research Centre of Lyon, INSERM U1052-CNRS, UMR5286, Lyon, France

Received: 19 July 2017 Accepted: 16 October 2017 Published: 23 October 2017

Chronic HBV infection affects more than 240 million people worldwide and is a major risk factor for developing cancer in which 10–30% of cases will progress towards liver cirrhosis and hepatocellular carcinoma. Infection outcome relies on the immune system maturity. Toll-like receptor 9 (TLR9) is a sensor of viral and bacterial DNA motifs and activates plasmacytoid dendritic cells (pDCs) and B cells to generate effective immune responses against infection. B cells, especially CD38^hi plasma cells play a major role in mediating humoral immune responses to clear HBV infection. Many studies have shown that TLR9 function is abrogated by HBV in pDCs. We aim to discuss the importance of B cell function in CHB patients and summarize concisely studies that describe the effect of HBV on TLR9 mediated B cell function. The effect of HBV on TLR9 activity in B cells should give insights into oncoviral immune escape strategies providing knowledge that will be essential to develop novel immunotherapeutic approaches.
- hepatitis B virus,
- chronic infection,
- B cells,
- Toll-like receptor 9,
- innate immunity
Citation: Issam Tout, Marie Marotel, Isabelle Chemin, Uzma Hasan. HBV and the importance of TLR9 on B cell responses[J]. AIMS Allergy and Immunology, 2017, 1(3): 124-137. doi: 10.3934/Allergy.2017.3.124

Related Papers:

Abstract

Chronic HBV infection affects more than 240 million people worldwide and is a major risk factor for developing cancer in which 10–30% of cases will progress towards liver cirrhosis and hepatocellular carcinoma. Infection outcome relies on the immune system maturity. Toll-like receptor 9 (TLR9) is a sensor of viral and bacterial DNA motifs and activates plasmacytoid dendritic cells (pDCs) and B cells to generate effective immune responses against infection. B cells, especially CD38^hi plasma cells play a major role in mediating humoral immune responses to clear HBV infection. Many studies have shown that TLR9 function is abrogated by HBV in pDCs. We aim to discuss the importance of B cell function in CHB patients and summarize concisely studies that describe the effect of HBV on TLR9 mediated B cell function. The effect of HBV on TLR9 activity in B cells should give insights into oncoviral immune escape strategies providing knowledge that will be essential to develop novel immunotherapeutic approaches.

References

[1]	Hepatitis B (2017) Available from: http://www.who.int/mediacentre/factsheets/fs204_Jul2014/en/.
[2]	Lavanchy D (2005) Worldwide epidemiology of HBV infection, disease burden, and vaccine prevention. J Clin Virol 34: S1–S3.
[3]	McMahon BJ (2005) Epidemiology and natural history of hepatitis B. Semin Liver Dis 25: 3–8. doi: 10.1055/s-2005-915644
[4]	Bertoletti A, Gehring AJ (2006) The immune response during hepatitis B virus infection. J Gen Viro l87: 1439–1449.
[5]	Dienstag JL (2008) Hepatitis B virus infection. New Engl J Med 359: 1486–1500. doi: 10.1056/NEJMra0801644
[6]	Mason WS, Aldrich C, Summers J, et al. (1982) Asymmetric replication of duck hepatitis B virus DNA in liver cells: free minus-strand DNA. Proc Natl Acad Sci USA 79: 3997–4001.
[7]	Summers J, Mason WS (1982) Replication of the genome of a hepatitis B-like virus by reverse transcription of an RNA intermediate. Cell 29: 403–415. doi: 10.1016/0092-8674(82)90157-X
[8]	Ganem D (2001) Virology. The X files--one step closer to closure. Science 294: 2299–2300.
[9]	European Association For The Study Of The Liver (2012) EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol 57: 167–185. doi: 10.1016/j.jhep.2012.02.010
[10]	Bertoletti A, Kennedy PT (2015) The immune tolerant phase of chronic HBV infection: new perspectives on an old concept. Cell Mol Immunol 12: 258–263. doi: 10.1038/cmi.2014.79
[11]	Bertoletti A, Ferrari C (2013) Innate and adaptive immune responses in chronic hepatitis B virus infections: towards restoration of immune control of viral infection. Postgrad Med J 89: 294–304. doi: 10.1136/postgradmedj-2011-301073rep
[12]	Guidotti LG, Chisari FV (2006) Immunobiology and pathogenesis of viral hepatitis. Annu Rev Pathol 1: 23–61. doi: 10.1146/annurev.pathol.1.110304.100230
[13]	McMahon BJ (2009) The influence of hepatitis B virus genotype and subgenotype on the natural history of chronic hepatitis B. Hepatol Int 3: 334–342. doi: 10.1007/s12072-008-9112-z
[14]	Buti M, Rodriguez-Frias F, Jardi R, et al. (2005) Hepatitis B virus genome variability and disease progression: the impact of pre-core mutants and HBV genotypes. J Clin Virol 34: S79–S82.
[15]	Sonneveld MJ, Rijckborst V, Zeuzem S, et al. (2012) Presence of precore and core promoter mutants limits the probability of response to peginterferon in hepatitis B e antigen-positive chronic hepatitis B. Hepatology 56: 67–75. doi: 10.1002/hep.25636
[16]	Tacke F, Gehrke C, Luedde T, et al. (2004) Basal core promoter and precore mutations in the hepatitis B virus genome enhance replication efficacy of Lamivudine-resistant mutants. J Virol 78: 8524–8535.
[17]	Alberti A, Diana S, Sculard GH, et al. (1978) Detection of a new antibody system reacting with Dane particles in hepatitis B virus infection. BMJ-Brit Med J 2: 1056–1058. doi: 10.1136/bmj.2.6144.1056
[18]	Loggi E, Gamal N, Bihl F, et al. (2014) Adaptive response in hepatitis B virus infection. J Viral Hepatitis 21: 305–313.
[19]	Hangartner L, Zinkernagel RM, Hengartner H (2006) Antiviral antibody responses: the two extremes of a wide spectrum. Nat Rev Immunol 6: 231–243. doi: 10.1038/nri1783
[20]	Seeger C, Mason WS (2000) Hepatitis B virus biology. Microbiol Mol Biol R 64: 51–68. doi: 10.1128/MMBR.64.1.51-68.2000
[21]	Weber B (2005) Genetic variability of the S gene of hepatitis B virus: clinical and diagnostic impact. J Clin Virol 32: 102–112.
[22]	Sayan M, Sentürk O, Akhan SÇ, et al. (2010) Monitoring of hepatitis B virus surface antigen escape mutations and concomitantly nucleos(t)ide analog resistance mutations in Turkish patients with chronic hepatitis B. Int J Infect Dis 14: e136–e141.
[23]	Mitchison NA (2004) T-cell-B-cell cooperation. Nat Rev Immunol 4: 308–312. doi: 10.1038/nri1334
[24]	Garraud O, Borhis G, Badr G, et al. (2012) Revisiting the B-cell compartment in mouse and humans: more than one B-cell subset exists in the marginal zone and beyond. BMC Immunol 13: 63. doi: 10.1186/1471-2172-13-63
[25]	LeBien TW, Tedder TF (2008) B lymphocytes: how they develop and function. Blood 112: 1570–1580. doi: 10.1182/blood-2008-02-078071
[26]	Das A, Ellis G, Pallant C, et al. (2012) IL-10-producing regulatory B cells in the pathogenesis of chronic hepatitis B virus infection. J Immunol 189: 3925–3935.
[27]	Xu X, Shang Q, Chen X, et al. (2015) Reversal of B-cell hyperactivation and functional impairment is associated with HBsAg seroconversion in chronic hepatitis B patients. Cell Mol Immunol 12: 309–316. doi: 10.1038/cmi.2015.25
[28]	Liu Y, Cheng LS, Wu S, et al. (2016) IL-10-producing regulatory B-cells suppressed effector T-cells but enhanced regulatory T-cells in chronic HBV infection. Clin Sci 130: 907–919. doi: 10.1042/CS20160069
[29]	Farci P, Diaz G, Chen Z, et al. (2010) B cell gene signature with massive intrahepatic production of antibodies to hepatitis B core antigen in hepatitis B virus-associated acute liver failure. Proc Natl Acad Sci USA 107: 8766–8771. doi: 10.1073/pnas.1003854107
[30]	Moir S, Ho J, Malaspina A, et al. (2008) Evidence for HIV-associated B cell exhaustion in a dysfunctional memory B cell compartment in HIV-infected viremic individuals. J Exp Med 205: 1797–1805. doi: 10.1084/jem.20072683
[31]	Weiss GE, Crompton PD, Li S, et al. (2009) Atypical memory B cells are greatly expanded in individuals living in a malaria-endemic area. J Immunol 183: 2176–2182.
[32]	Oliviero B, Cerino A, Varchetta S, et al. (2011) Enhanced B-cell differentiation and reduced proliferative capacity in chronic hepatitis C and chronic hepatitis B virus infections. J Hepatol 55: 53–60. doi: 10.1016/j.jhep.2010.10.016
[33]	Moir S, Fauci AS (2009) B cells in HIV infection and disease. Nat Rev Immunol 9: 235–245. doi: 10.1038/nri2524
[34]	Suarez F, Lortholary O, Hermine O, et al. (2006) Infection-associated lymphomas derived from marginal zone B cells: a model of antigen-driven lymphoproliferation. Blood 107: 3034–3044. doi: 10.1182/blood-2005-09-3679
[35]	Maruyama T, McLachlan A, Iino S, et al. (1993) The serology of chronic hepatitis B infection revisited. J Clin Invest 91: 2586–2595. doi: 10.1172/JCI116497
[36]	Böcher WO, Herzog-Hauff S, Herr W, et al. (1996) Regulation of the neutralizing anti-hepatitis B surface (HBs) antibody response in vitro in HBs vaccine recipients and patients with acute or chronic hepatitis B virus (HBV) infection. Clin Exp Immunol 105: 52–58. doi: 10.1046/j.1365-2249.1996.d01-732.x
[37]	Dusheiko GM, Hoofnagle JH, Cooksley WG, et al. (1983) Synthesis of antibodies to hepatitis B virus by cultured lymphocytes from chronic hepatitis B surface antigen carriers. J Clin Invest 71: 1104–1113. doi: 10.1172/JCI110860
[38]	Barnaba V, Valesini G, Levrero M, et al. (1985) Immunoregulation of the in vitro anti-HBs antibody synthesis in chronic HBsAg carriers and in recently boosted anti-hepatitis B vaccine recipients. Clin Exp Immunol 60: 259–266.
[39]	Barnaba V, Levrero M, Ruberti G, et al. (1987) In vitro anti-HBs antibody synthesis from anti-hepatitis B vaccine recipients. Clin Exp Immunol 70: 283–288.
[40]	Amu S, Ruffin N, Rethi B, et al. (2013) Impairment of B-cell functions during HIV-1 infection. Aids 27: 2323–2334.
[41]	Pensieroso S, Galli L, Nozza S, et al. (2013) B-cell subset alterations and correlated factors in HIV-1 infection. Aids 27: 1209–1217.
[42]	Ni J, Hembrador E, Di BA, et al. (2003) Accumulation of B lymphocytes with a naive, resting phenotype in a subset of hepatitis C patients. J Immunol 170: 3429–3439.
[43]	Racanelli V, Frassanito MA, Leone P, et al. (2006) Antibody production and in vitro behavior of CD27-defined B-cell subsets: persistent hepatitis C virus infection changes the rules. J Virol 80: 3923–3934. doi: 10.1128/JVI.80.8.3923-3934.2006
[44]	Rosa D, Saletti G, Gregorio ED, et al. (2005) Activation of naïve B lymphocytes via CD81, a pathogenetic mechanism for hepatitis C virus-associated B lymphocyte disorders. Proc Natl Acad Sci USA 102: 18544–18549. doi: 10.1073/pnas.0509402102
[45]	Wang XD, Wang L, Ji FJ, et al. (2012) Decreased CD27 on B lymphocytes in patients with primary hepatocellular carcinoma. J Int Med Res 40: 307–316. doi: 10.1177/147323001204000131
[46]	Li WY, Jiang YF, Jin QL, et al. (2010) Immunologic characterization of posthepatitis cirrhosis caused by HBV and HCV infection. J Biomed Biotechnol 2010: 138237.
[47]	Lund FE (2008) Cytokine-producing B lymphocytes-key regulators of immunity. Curr Opin Immunol 20: 332–338. doi: 10.1016/j.coi.2008.03.003
[48]	Llorente L, Zou W, Levy Y, et al. (1995) Role of interleukin 10 in the B lymphocyte hyperactivity and autoantibody production of human systemic lupus erythematosus. J Exp Med 181: 839–844. doi: 10.1084/jem.181.3.839
[49]	Kakumu S, Shinagawa T, Ishikawa T, et al. (1991) Serum interleukin 6 levels in patients with chronic hepatitis B. Am J Gastroenterol 86: 1804–1808.
[50]	Aspord C, Bruder CJ, Jacob MC, et al. (2016) Remodeling of B-cell subsets in blood during pegylated IFNα-2a therapy in patients with chronic Hepatitis B infection. PloS One 11: e0156200. doi: 10.1371/journal.pone.0156200
[51]	Chang JJ, Wightman F, Bartholomeusz A, et al. (2005) Reduced hepatitis B virus (HBV)-specific CD4+ T-cell responses in human immunodeficiency virus type 1-HBV-coinfected individuals receiving HBV-active antiretroviral therapy. J Virol 79: 3038–3051. doi: 10.1128/JVI.79.5.3038-3051.2005
[52]	Maini MK, Boni C, Lee CK, et al. (2000) The role of virus-specific CD8 (+) cells in liver damage and viral control during persistent hepatitis B virus infection. J Exp Med 191: 1269–1280. doi: 10.1084/jem.191.8.1269
[53]	Boni C, Penna A, Ogg GS, et al. (2001) Lamivudine treatment can overcome cytotoxic T-cell hyporesponsiveness in chronic hepatitis B: new perspectives for immune therapy. Hepatology 33: 963–971.
[54]	Chen L, Zhang Z, Chen W, et al. (2007) B7-H1 up-regulation on myeloid dendritic cells significantly suppresses T cell immune function in patients with chronic hepatitis B. J Immunol 178: 6634–6641.
[55]	Takeuchi O, Akira S (2010) Pattern recognition receptors and inflammation. Cell 140: 805–820. doi: 10.1016/j.cell.2010.01.022
[56]	Hua Z, Hou B (2013) TLR signaling in B-cell development and activation. Cell Mol Immunol 10: 103–106. doi: 10.1038/cmi.2012.61
[57]	Bernasconi NL, Onai N, Lanzavecchia A (2003) A role for Toll-like receptors in acquired immunity: up-regulation of TLR9 by BCR triggering in naive B cells and constitutive expression in memory B cells. Blood 101: 4500–4504. doi: 10.1182/blood-2002-11-3569
[58]	Ruprecht CR, Lanzavecchia A (2006) Toll-like receptor stimulation as a third signal required for activation of human naive B cells. Eur J Immunol 36: 810–816.
[59]	Hirsch I, Caux C, Hasan U, et al. (2010) Impaired Toll-like receptor 7 and 9 signaling: from chronic viral infections to cancer. Trends Immunol 31: 391–397. doi: 10.1016/j.it.2010.07.004
[60]	Chen Z, Cheng Y, Xu Y, et al. (2008) Expression profiles and function of Toll-like receptors 2 and 4 in peripheral blood mononuclear cells of chronic hepatitis B patients. Clin Immunol 128: 400–408.
[61]	Fathallah I, Parroche P, Gruffat H, et al. (2010) EBV latent membrane protein 1 is a negative regulator of TLR9. J Immunol 185: 6439–6447.
[62]	Hasan UA, Zannetti C, Parroche P, et al. (2013) The human papillomavirus type 16 E7 oncoprotein induces a transcriptional repressor complex on the Toll-like receptor 9 promoter. J Exp Med 210: 1369–1387. doi: 10.1084/jem.20122394
[63]	Wieland S, Thimme R, Purcell RH, et al. (2004) Genomic analysis of the host response to hepatitis B virus infection. Proc Natl Acad Sci USA 101: 6669–6674. doi: 10.1073/pnas.0401771101
[64]	Dunn C, Peppa D, Khanna P, et al. (2009) Temporal analysis of early immune responses in patients with acute hepatitis B virus infection. Gastroenterology 137: 1289–1300. doi: 10.1053/j.gastro.2009.06.054
[65]	Cheng J, Imanishi H, Morisaki H, et al. (2005) Recombinant HBsAg inhibits LPS-induced COX-2 expression and IL-18 production by interfering with the NFkappaB pathway in a human monocytic cell line, THP-1. J Hepatol 43: 465–471. doi: 10.1016/j.jhep.2005.02.033
[66]	Müller C, Zielinski CC (1990) Impaired lipopolysaccharide-inducible tumor necrosis factor production in vitro by peripheral blood monocytes of patients with viral hepatitis. Hepatology 12: 1118–1124.
[67]	Wang S, Chen Z, Hu C, et al. (2013) Hepatitis B virus surface antigen selectively inhibits TLR2 ligand-induced IL-12 production in monocytes/macrophages by interfering with JNK activation. J Immunol 190: 5142–5151.
[68]	Ml ODB, Binda RS, van Roosmalen MH, et al. (2009) Hepatitis B virus surface antigen impairs myeloid dendritic cell function: a possible immune escape mechanism of hepatitis B virus. Immunology 126: 280–289. doi: 10.1111/j.1365-2567.2008.02896.x
[69]	Vincent IE, Zannetti C, Lucifora J, et al. (2011) Hepatitis B virus impairs TLR9 expression and function in plasmacytoid dendritic cells. PloS One 6: e26315. doi: 10.1371/journal.pone.0026315
[70]	Xu Y, Hu Y, Shi B, et al. (2009) HBsAg inhibits TLR9-mediated activation and IFN-alpha production in plasmacytoid dendritic cells. Mol Immunol 46: 2640–2646. doi: 10.1016/j.molimm.2009.04.031
[71]	Han Q, Zhang C, Zhang J, et al. (2013) The role of innate immunity in HBV infection. Semin Immunopathol 35: 23–38. doi: 10.1007/s00281-012-0331-y
[72]	Lang T, Lo C, Skinner N, et al. (2011) The hepatitis B e antigen (HBeAg) targets and suppresses activation of the toll-like receptor signaling pathway. J Hepatol 55: 762–769. doi: 10.1016/j.jhep.2010.12.042
[73]	Visvanathan K, Skinner NA, Thompson AJV, et al. (2007) Regulation of Toll-like receptor-2 expression in chronic hepatitis B by the precore protein. Hepatology 45: 102–110. doi: 10.1002/hep.21482
[74]	Wu J, Meng Z, Jiang M, et al. (2009) Hepatitis B virus suppresses toll-like receptor-mediated innate immune responses in murine parenchymal and nonparenchymal liver cells. Hepatology 49: 1132–1140.
[75]	Luangsay S, Gruffaz M, Isorce N, et al. (2015) Early inhibition of hepatocyte innate responses by hepatitis B virus. J Hepatol 63: 1314–1322. doi: 10.1016/j.jhep.2015.07.014
[76]	Jegaskanda S, Ahn SH, Skinner N, et al. (2014) Downregulation of interleukin-18-mediated cell signaling and interferon gamma expression by the hepatitis B virus e antigen. J Virol 88: 10412–10420. doi: 10.1128/JVI.00111-14
[77]	Yu S, Chen J, Wu M, et al. (2010) Hepatitis B virus polymerase inhibits RIG-I- and Toll-like receptor 3-mediated beta interferon induction in human hepatocytes through interference with interferon regulatory factor 3 activation and dampening of the interaction between TBK1/IKKepsilon and DDX3. J Gen Virol 91: 2080–2090. doi: 10.1099/vir.0.020552-0
[78]	Hepatitis B virus polymerase suppresses NF-κB signaling by inhibiting the activity of IKKs via interaction with Hsp90β. Available from: https://www-ncbi-nlm-nih-gov.gate2.inist.fr/pubmed?term=Hepatitis%20B%20virus%20polymerase%20suppresses%20NF-kappaB%20signaling%20by%20inhibiting%20the%20activity%20of%20IKKs%20via%20interaction%20with%20Hsp90beta%5BTitle%5D.
[79]	Wang H, Ryu WS (2010) Hepatitis B virus polymerase blocks pattern recognition receptor signaling via interaction with DDX3: implications for immune evasion. PLoS Pathog 6: e1000986. doi: 10.1371/journal.ppat.1000986
[80]	Martinet J, Dufeu-Duchesne T, Bruder CJ, et al. (2012) Altered functions of plasmacytoid dendritic cells and reduced cytolytic activity of natural killer cells in patients with chronic HBV infection. Gastroenterology 143: 1586–1596. doi: 10.1053/j.gastro.2012.08.046
[81]	Xu N, Yao HP, Lv GC, et al. (2012) Downregulation of TLR7/9 leads to deficient production of IFN-α from plasmacytoid dendritic cells in chronic hepatitis B. Inflamm Res 61: 997–1004.
[82]	Ratnam DT, Sievert W, Visvanathan K (2012) Natural killer cells display impaired responses to toll like receptor 9 that support viral persistence in chronic hepatitis B. Cell Immunol 279: 109–115. doi: 10.1016/j.cellimm.2012.09.005
[83]	Wang K, Liu H, He Y, et al. (2010) Correlation of TLR1-10 expression in peripheral blood mononuclear cells with chronic hepatitis B and chronic hepatitis B-related liver failure. Hum Immunol 71: 950–956. doi: 10.1016/j.humimm.2010.07.013
[84]	Zhou J, Huang Y, Tian D, et al. (2009) Expression of toll-like receptor 9 in peripheral blood mononuclear cells from patients with different hepatitis B and C viral loads. J Huazhong University Sci Technol Med Sci 29: 313–317. doi: 10.1007/s11596-009-0310-2
[85]	Xie Q, Shen HC, Jia NN, et al. (2009) Patients with chronic hepatitis B infection display deficiency of plasmacytoid dendritic cells with reduced expression of TLR9. Microbes Infect 11: 515–523.
[86]	Huang YW, Hsu CK, Lin SC, et al. (2014) Reduced toll-like receptor 9 expression on peripheral CD14+ monocytes of chronic hepatitis B patients and its restoration by effective therapy. Antivir Ther 19: 637–643. doi: 10.3851/IMP2762
[87]	Xu N, Yao H, Sun Z, et al. (2008) Toll-like receptor 7 and 9 expression in peripheral blood mononuclear cells from patients with chronic hepatitis B and related hepatocellular carcinoma. Acta Pharmacol Sin 29: 239–244. doi: 10.1111/j.1745-7254.2008.00711.x
[88]	Zhao PW, Ma L, Ji HF, et al. (2015) The expression of TLR-9, CD86, and CD95 phenotypes in circulating B cells of patients with chronic viral hepatitis B or C before and after antiviral therapy. Mediat Inflamm 2015: 762709.
[89]	Wang G, Liu Y, Huang R, et al. (2017) Characteristics of regulatory B cells in patients with chronic hepatitis B virus infection in different immune phases. Discov Med 23: 295–304.
[90]	Takeshita F, Suzuki K, Sasaki S, et al. (2004) Transcriptional regulation of the human TLR9 gene. J Immunol 173: 2552–2561.
[91]	Aoyama T, Paik YH, Seki E (2010) Toll-like receptor signaling and liver fibrosis. Gastroenterol Res Pract 2010: E1–E8.

Reader Comments

Your name:*

Email:*
© 2017 the Author(s), licensee AIMS Press. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0)